» Articles » PMID: 33426406

MiRNA Expression and Interaction with the 3'UTR of FMR1 in FRAXopathy Pathogenesis

Overview
Date 2021 Jan 11
PMID 33426406
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

FRAXopathies are caused by the expansion of the CGG repeat in the 5'UTR of the gene, which encodes the protein responsible for the synthesis of FMRP. This mutation leads to dramatic changes in FMRP expression at both the mRNA and protein levels. Evidence is emerging that changes in mRNA expression can lead to the dysregulation of the miRNAs that target its 3'UTR. In the present work, B-lymphocyte cell lines obtained from patients with FRAXopathies were used, and a wide variety of gene activities were observed, allowing the identification of the relationships between dysregulation and miRNA activity. We studied the expression levels of eight miRNAs that target the gene. To prove the interaction of the studied miRNAs with , a plasmid was constructed that possesses three primary structures: the miRNA gene, with expression driven by an inducible promoter; a constitutively expressed FusionRed reporter; and an eGFP reporter followed by the 3'UTR of the gene. We evaluated changes in miRNA expression in response to alterations in gene activity in a model cell line as well as interactions with some miRNAs with the 3'UTR.

Citing Articles

Regulation of Bone Morphogenetic Protein Receptor Type II Expression by /Fragile X Mental Retardation Protein in Human Granulosa Cells in the Context of Poor Ovarian Response.

Nguyen X, Vilkaite A, Bender U, Dietrich J, Hinderhofer K, Strowitzki T Int J Mol Sci. 2024; 25(19).

PMID: 39408972 PMC: 11477111. DOI: 10.3390/ijms251910643.


The Prognostic and Therapeutic Potential of Fragile X Mental Retardation 1 () Gene Expression in Prostate Adenocarcinoma: Insights into Survival Outcomes and Oncogenic Pathway Modulation.

Baldi S, Amer B, Alnadari F, Al-Mogahed M, Gao Y, Gamallat Y Int J Mol Sci. 2024; 25(13).

PMID: 39000397 PMC: 11242135. DOI: 10.3390/ijms25137290.


Phenotypic variability to medication management: an update on fragile X syndrome.

Elhawary N, AlJahdali I, Abumansour I, Azher Z, Falemban A, Madani W Hum Genomics. 2023; 17(1):60.

PMID: 37420260 PMC: 10329374. DOI: 10.1186/s40246-023-00507-2.


A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome.

Straub D, Schmitt L, Boggs A, Horn P, Dominick K, Gross C Sci Rep. 2023; 13(1):3808.

PMID: 36882476 PMC: 9992378. DOI: 10.1038/s41598-023-29786-4.


Molecular Pathogenesis and Peripheral Monitoring of Adult Fragile X-Associated Syndromes.

Valor L, Morales J, Hervas-Corpion I, Marin R Int J Mol Sci. 2021; 22(16).

PMID: 34445074 PMC: 8395059. DOI: 10.3390/ijms22168368.


References
1.
Tassone F, Iwahashi C, Hagerman P . FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol. 2006; 1(2):103-5. DOI: 10.4161/rna.1.2.1035. View

2.
Taguchi Y . MicroRNA-mediated regulation of target genes in several brain regions is correlated to both microRNA-targeting-specific promoter methylation and differential microRNA expression. BioData Min. 2013; 6(1):11. PMC: 3693885. DOI: 10.1186/1756-0381-6-11. View

3.
Brendel C, Mielke B, Hillebrand M, Gartner J, Huppke P . Methotrexate treatment of FraX fibroblasts results in FMR1 transcription but not in detectable FMR1 protein levels. J Neurodev Disord. 2013; 5(1):23. PMC: 3846751. DOI: 10.1186/1866-1955-5-23. View

4.
Xie H, Xu T, Chen Y, Li Y, Xia Y, Xu S . New perspectives for multi-level regulations of neuronal acetylcholinesterase by dioxins. Chem Biol Interact. 2016; 259(Pt B):286-290. DOI: 10.1016/j.cbi.2016.06.030. View

5.
Chtarto A, Yang X, Bockstael O, Melas C, Blum D, Lehtonen E . Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Exp Neurol. 2007; 204(1):387-99. DOI: 10.1016/j.expneurol.2006.11.014. View